TRAIL resistant pancreatic cancer cell lines show a higher basal and inducible NF-κB activity compared to sensitive cell lines [6,7] and TRAIL treatment induces CX3CL1 expression in these cells. The gene discussed is CX3CL1; the disease is pancreatic neoplasm.